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Objective: Percutaneous pulmonary valve replacement has been recently introduced into clinical practice.
Patients with transcatheter pulmonary valve replacement will definitely face the problems of valve degeneration.
In addition to surgical re-replacement of the degenerated bioprosthetic valves, we studied the replacement of
degenerated bioprosthetic valves with transcatheter reimplantation of stent-mounted pulmonary valves.
Methods: Percutaneous pulmonary valve replacement was first performed in 6 sheep used a homemade valved
stent. Two months after the initial procedure, the 6 sheep previously implanted with a valved stent underwent the
same implantation procedure of a pulmonary valved stent. Hemodynamic assessment of the bioprosthetic pulmo-
nary valve was obtained by echocardiography immediately post-implant and at 2 months follow-up.
Results: All 6 sheep had successful transcatheter stent-mounted pulmonary valve replacement in the first exper-
iment. After 2 months, reimplantation was successful in 5 sheep but failed in 1 sheep because the first valved stent
was pushed to the bifurcation of the pulmonary artery by the delivery sheath. Echocardiography confirmed the
stents were in the desired position during the follow-up. The remaining 5 sheep with normal valvular and cardiac
functionality survived for 3 months after implantation.
Conclusion: Transcatheter stent-mounted bioprosthetic pulmonary valve reimplantation is feasible in an animal
model and more convenient than open chest reimplantation.E
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SSince the first case of transcatheter pulmonary valve replace-
ment was reported in 2000,1 bioprosthetic valves have
become popular for use in clinical transcatheter valve
replacement.2,3 Bioprosthetic valves used in clinical trans-
catheter valve replacement are made according to the same
standard as the bioprosthetic valves used in surgical valve
replacement in terms of valve tissue processing, shaping,
and sewing technology. They have good hemodynamic
characteristics and do not routinely require long-term antico-
agulation. The incidence of thrombosis and other complica-
tions related to the valve itself is less than with mechanical
valves. Their use in open chest valve replacement is gradu-
ally increasing. However, bioprosthetic valves have a higher
rate of structural degeneration than homografts, thereby lim-
iting their clinical application. With the development in
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opment in research on bioprosthetic valve durability in
recent years, 10- and 15-year survivals for patients have
increased to the same level as those for mechanical valve
replacement. A recent report showed that the 20-year sur-
vival with bovine pericardial valve implantation was more
than 90%, which is obviously better than that with bileaflet
mechanical valves.4 However, there is still debate on the life
expectancy of bioprosthetic valves.
Transcatheter valve replacement was only recently intro-
duced into clinical practice. Compared with surgical valve
replacement, transcatheter valve replacement is less inva-
sive. When the initial bioprosthetic valves inserted by
a catheter have degenerated, how does one deal with the de-
generated bioprosthetic valves? To date, a surgical approach
is the only option for replacing a degenerated bioprosthetic
valve. However, reoperation usually involves more clinical
difficulties and higher risk. There are few studies on its
application when the initial bioprosthetic valve inserted
by a catheter has degenerated. Therefore, we studied the
replacement of degenerated bioprosthetic valves with trans-
catheter reimplantation of stent-mounted pulmonary valves
with the aim of providing data for clinical practice.
MATERIALS AND METHODS
Percutaneous Stent-Mounted Pulmonary Valve
Replacement
Six healthy and hygienic sheep (3 female and 3 male, weighing 26.1 
3.7 kg) provided by the animal center of the Navy Medicine Researchardiovascular Surgery c Volume 138, Number 3 733
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SInstitute (License No. 2002-044) were used in this study. The animals were
not fed for 8 hours before the operation. After intramuscular injection of ket-
amine (10 mg/kg) and diazepam (5 mg), a venous transfusion access on the
foreleg was established. Anesthesia was maintained by intravenous
injection of 2.5% sodium pentobarbital. All procedures were performed
in the dorsal recumbent position. The right femoral vein was prepared for
catheterization. Electrocardiograms were routinely monitored throughout
the whole procedure. The study was approved by the local institutional
ethics committee. All handling of the experimental animals conformed to
the ‘‘Experimental Animal Act of Administration’’ promulgated by the
National Science and Technology Committee in 1988. The stent-mounted
valves were implanted in the pulmonary valve position through catheter-
ization via the right femoral vein. The details of the stent and implantation
procedure have been reported.5 After the procedure, the sheep were re-
turned to the controlled animal facility, where their general health was
checked daily. The sheep were fed routinely for 2 months after the exper-
iment and were given an intramuscular injection of penicillin 800,000
units twice daily for 3 days to prevent infection, subcutaneous injection
of heparin (2500 IU) twice daily for 3 days, and aspirin 3 mg/kg orally
every day.
Transcatheter Reimplantation of Stent-Mounted
Pulmonary Valve
Two months after the initial procedure, the sheep with valves implanted
underwent the same preparation for catheterization and anesthesia. Hemo-
dynamic assessment of the right ventricular outflow tract and assessment734 The Journal of Thoracic and Cardiovascular Suof the condition of the bioprosthetic pulmonary valve were obtained by
echocardiography through the parasternal long-axis view.
An incision of the left femoral vein was made, and a 7F sheath was
inserted into the vein. A 6F pigtail cardiac catheter was inserted through
the sheath. Angiography of the prosthetic pulmonary valve was performed
(pressure 800 psi, total amount of contrast 20 mL, speed 20mL/s) to identify
the position of the previously implanted stent and to measure the diameter of
the prosthetic pulmonary valve. After a guidewire was positioned in the dis-
tal section of the left or right pulmonary artery, a 14F delivery system was
then advanced into the pulmonary artery over the guidewire. The implanta-
tion was similar to the previous procedure. Thereafter, the stent was
deployed inside the valved stent implanted previously. The delivery system
was then removed (Figure 1). The procedure ended with angiographic stud-
ies and hemodynamic assessment in the right ventricle and prosthetic pul-
monary valve. All animals were given an intramuscular injection with
penicillin 800,000 units after the procedure.
Clinical Evaluation of Stent-Mounted Pulmonary
Valve Reimplantation
After reimplanting the stent-mounted pulmonary valve, esophageal
echocardiography was performed immediately to assess the function of
the prosthetic valve and hemodynamics in the right parasternal long-axis
view through the right ventricular outflow tract.
After 2 months, echocardiography was performed again with the same
views as before to assess the cardiac function, function of the prosthetic
valve, and blood flow velocity in different parts of the stent.FIGURE 1. Valve stent reimplantation process (representative images). A, The first valved stent in the pulmonary valve annulus. B, The guidewire was
deployed across the previous valved stent. C, The second valved stent was delivered to the previously noted location of the pulmonary valve. D, The delivery
sheath was retracted, and the second valved stent was released.rgery c September 2009
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Results of Implantation
All 6 sheep had successful transcatheter stent-mounted
pulmonary valve replacement in the first experiment. After
2 months, the sheep underwent the second valved stent
implantation. Reimplantation was successful in 5 sheep
but failed in 1 sheep because the first valved stent was
pushed to the bifurcation of the pulmonary artery by the
delivery sheath.
The mean pulmonary valve diameter was 14.7  0.9 mm
as measured by echocardiography before implantation and
15.6  1.1 mm as measured by angiography from a body
position of 90 degrees left anterior oblique during the
implantation. In the first implantation and the reimplanta-
tion, the mean diameter at the neck of the valved stent was
19.7  2.0 mm. The mean duration of the reimplantation
was 55.2  6.8 minutes. The mean duration of x-ray expo-
sure was 10.5  2.0 minutes.
Assessment of the Reimplantation Immediately After
the Operation
Esophageal echocardiography performed immediately
after reimplantation showed the following: The position of
the prosthetic valve was ideal, the valvular function was nor-
mal, there was no regurgitation, and the 2 valved stents were
in close contact (Figure 2). On x-ray examination, the
2 valved stents overlapped completely. Angiography in the
right ventricle showed that the position of the stents was
good. There was no regurgitation involving the prosthetic
pulmonary valve (Figure 3).
Assessment Two Months After Reimplantation
At 2 months after reimplantation, 5 of the experimental
sheep were growing well. They ate normally and had gained
4 to 6 kg of body weight. Echocardiography showed that the
FIGURE 2. Echocardiography shows the 2 valved stents overlapped com-
pletely and contacted each other very closely immediately after the reim-
plantation.The Journal of Thoracic and Cvalves had normal closure function. Four animals had no
regurgitation, and 1 animal had mild regurgitation. The
hemodynamics in the valve, over the valve, and in the far
section of the stent among all 5 animals that had stent-
mounted pulmonary valve implantation were similar
(Table 1). The ejection fraction was normal (67.3%–
71.5%) (Figure 4).
DISCUSSION
In the late 1980s, tissue processing for surgical biopros-
thetic valves was developed comprehensively. Although
the rate of use has increased, many young patients cannot
avoid reimplantation of a bioprosthetic valve because of
valve degeneration.6,7 The development of transcatheter pul-
monary valve implantation progressed with accumulation of
surgical experience and improvement in catheterization
equipment;8 however, some problems associated with surgi-
cal implantation, such as bioprosthetic valve deterioration
FIGURE 3. Angiography of pulmonary artery. There was no regurgitation
involving the 2 prosthetic pulmonary valves immediately after the
reimplantation.
TABLE 1. Peak velocity across the valved stent and heart function
assessed by ultrasound 2 months after procedure
Sheep
no.
Velocity in
valve orifice
(cm/s)
Velocity in
midpiece of
stent (cm/s)
Velocity in
distal segment
of stent (cm/s) RVEF (%)
1 226 237 196 70.5
2 240 243 235 67.3
3 242 248 245 71.2
4 230 234 225 68.5
5a — — — —
6 240 238 236 71.5
RVEF, Right ventricular ejection fraction. aReimplantation of valved stent failed in
sheep number 5.ardiovascular Surgery c Volume 138, Number 3 735
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SFIGURE 4. Echocardiography evaluation 2 months after reimplantation. A, One sheep had mild regurgitation detected by pulsed-wave Doppler. B, Normal
ejection fraction is shown by M-mode echocardiography.and calcification, also occur in transcatheter valve implanta-
tion.9,10 In addition to valve deterioration, the metal part of
a valved stent can have metal fatigue. If the stent is placed
near the right ventricle outflow tract, there may be more
extrusion and it may be easily broken. Once a stent is broken,
its valvular function will inevitably be affected.
At present, most patients with transcatheter pulmonary
valve replacement are relatively young.After a certain number
of years, patients will definitely face the problems of valve
degeneration and metal fatigue of the stent. Most of these
patients have already undergone open chest surgery once or
twice, and surgical valve reimplantation incurs a higher risk.11
This study used sheep with 2-month transcatheter valve
stent implantation as an experimental model to simulate
valve degeneration and stent wear, and then reimplantation
of a valved stent to achieve the ‘‘valve in valve’’ effect.
This study demonstrated 2 problems that remain with the
procedure. 1) The position of the stent implanted initially
may be affected by the second stent implantation. Therefore,
the procedure must be carefully performed. In particular, the
sheath holding the second stent must be introduced by
guidewire into the initial stent and should not be pushed
into the stent directly. In this study, there was 1 case in which
the first stent was pushed to the bifurcation of the pulmonary
artery by the sheath. On the one hand, this was related to the
contact between the sheath and the stent. On the other hand,
the first stent had been implanted for only 2 months, and the
host endothelial cells and fibrosis tissue barely covered the
valved stent, so the stent easily migrated. 2) The second
problem concerns how to choose the size of the stent for
reimplantation. The diameter of the stent implanted initially
was bigger than that of the pulmonary artery so that it could
expand the pulmonary artery and fit firmly. If the stent for
reimplantation is bigger than the first stent, the pulmonary
artery may be expanded excessively. The ideal size of the
second stent should be the same as the first stent, which
would not only allow the 2 stents to contact each other prop-
erly but also avoid excessive expansion of the pulmonary736 The Journal of Thoracic and Cardiovascular Surartery. In this study, we used the same sized stent for initial
implantation and reimplantation. After follow-up for
2 months, hemodynamics, valvular function, and cardiac
function were normal in the reimplanted valved stent. There
were no complications, such as valve relocation. Therefore,
use of the same sized stent for both implantations is feasible.
Our preliminary data also showed that the new type of
valved stent was flexible and could be successfully
implanted through a catheter 2 or 3 times.
Study Limitations
Although this study provided some positive experimental
results, the study design had certain limitations. The reimplan-
tation was performed too early in that the initially implanted
valve was still working normallywithout wear and tear. These
animals have no pulmonary stenosis that would likely be the
indication for redo pulmonary valve replacement.With regard
to pulmonary stenosis, balloon valvuloplasty may be neces-
sary before valve reimplantation. Therefore, under such cir-
cumstances the application of reimplantation to other
circumstances is limited. The small sample size in our study
is also an obvious limitation. Larger cohorts and longer fol-
low-up durations are needed to provide sufficient reference
data for potential clinical application.
CONCLUSIONS
Transcatheter stent-mounted bioprosthetic pulmonary
valve reimplantation is feasible and more convenient than
open chest reimplantation. It may become an alternative
treatment for young patients with valvular deterioration.
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